Diabetes mellitus is an independent risk factor for HF,45 with studies showing that subclinical atherosclerotic and nonatherosclerotic myocardial damage occurs early in the natural history of diabetes mellitus, often before diagnosis of the condition.46 SGLT‐2 inhibitors are approved for the management of type 2 diabetes mellitus (T2D) and have recently been investigated in several large, placebo‐controlled trials for cardiovascular safety as well as efficacy in patients with T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.